Skip to content

A Trial of Esophageal and Gastric Stenting for Leak or Perforation

A Phase II Trial of Esophageal and Gastric Stenting for Leak or Perforation

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01107249
Acronym
ESO-stent
Enrollment
10
Registered
2010-04-20
Start date
2010-05-31
Completion date
2014-10-31
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal or Gastric Leaks, Esophageal or Gastric Perforations

Keywords

esophageal, stenting, perforations, gastric, esophageal stenting

Brief summary

Long term follow-up of patients treated for esophageal fistulas with a newer occlusive self-expanding covered metal stents compared to traditional stents.

Detailed description

This study is written to evaluate our experience treating esophageal fistulas with occlusive self-expanding covered metal stents. The long-term outcomes of patients treated with this new type of stent are as yet unknown. The differences between these stents is also unknown, as well as the ease of removal, efficacy, and/or placement. The intent of this study is not to determine which stent is better, but to merely evaluate the use of both. With this in mind, there will be no randomization of stent use, nor will there be restrictions on which stent may be used in which setting. This will be left to the judgment of the clinical placing the stent.

Interventions

DEVICEBoston Scientific Ultraflex or Wallstent stents

Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.

Sponsors

The Methodist Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients must have radiographic or endoscopic proof of an esophageal leak or fistula. 2. Patients will be required to undergo imaging with CT scan, endoscopy, or fluoroscopy to investigate the leak. Once the location of the leak is identified, then patients must be taken for stenting and any adjunctive treatment within 12 hours of diagnosis or within 12 hours of arrival to The Methodist Hospital. 3. Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital.

Exclusion criteria

1. Patients who will not agree to return for routine follow-up and studies. 2. Patients who will not tolerate an endobronchial ultrasound or endoscopic procedure (coagulopathy \[INR\>1.8, PTT\>60, or platelet level \<50\], hemodynamically unstable \[MAP\<50 or SBP\<80\], or other medical illness precluding safe endoscopy). 3. Patients who have a perforation too high to stent (such as the back of the pharynx, where a stent is not able to be placed), the only unfavorable anatomic location is this one listed above; we believe all other locations are amenable to stent placement. 4. Resectable carcinoma, megaesophagus, severe stricture, or caustic ingestion.

Design outcomes

Primary

MeasureTime frameDescription
Safety of esophageal stenting by conducting an Omnipaque swallow and by the success of leakage stops and fistula healing.15 - 30 daysBy results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.
Efficacy of esophageal stenting by the success of leakage stops and fistula healing.15 - 30 daysBy results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.
A 30 day duration of stent placement and the relation to the healing esophagus30 daysBy results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. Evaluation of the healing process of the esophagus within first 30 days with the capability of its removal procedure. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.

Secondary

MeasureTime frameDescription
An institutional protocol for stent management1 yearResults will be considered for assessing and instituting an institutional protocol to become the standard of care for future patient situations.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026